<DOC>
	<DOCNO>NCT02616874</DOCNO>
	<brief_summary>The BCN02-Romi study aim evaluate combine `` kick kill '' strategy use immunogenic candidate vaccine available far ( HIVconsv ) strong latency reversal agent available present time ( romidepsin ) cohort early-treated HIV positive individual .</brief_summary>
	<brief_title>Study Evaluate Safety Effect HIVconsv Vaccines Combination With Histone Deacetylase Inhibitor Romidepsin Viral Rebound Kinetic After Treatment Interruption Early Treated HIV-1 Infected Individuals</brief_title>
	<detailed_description>The combine use therapeutic vaccination specific drug reactivate latent virus reservoir ( Kick kill strategy ) hold promise achieve functional cure viral eradication HIV infection . The present project consist proof-of-concept clinical trial cohort 24 early treat HIV-1 infected individual rolled-over BCN01 vaccine clinical trial participant receive immunogenic vaccine test date , ChAd modify vaccinia Ankara ( MVA ) .HIVconsv vaccine . All individual give booster immunization MVA.HIVconsv combination romidepsin ( RMD ) , potent histone deacetylation inhibitor ( HDACi ) later undergo monitor antiretroviral pause . HIVconsv vaccine specifically design stimulate broad potent cytotoxic T cell ( CTL ) response towards conserve viral region HIV-1 proteome , recently suggest crucial role target HIV variant harbour latent reservoir mutation escape T-cell immune response . The study include development population pharmacokinetic/pharmacodynamic ( PK/PD ) substudy analyse vivo effect RMD induction HIV expression rest cell , deeply investigate unintended effect CTL function well predict relationship RMD exposure effect . The investigator ' result allow investigator optimize RMD dosing , evaluate clinical efficacy eradication strategy cART interruption identify good correlate control rebound viremia cessation treatment .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>1 . Subject include ChAdMVA.HIVconsv_BCN01 study complete followup include BCN01RO extension study . 2 . Optimal virological suppression least 3 years.cop/ml ) . 3 . Being nonboosted integraseinhibitor base regimen ( raltegravir dolutegravir ) least 4 week screen visit . 4 . Haematological biochemical laboratory parameter follow : Haemoglobin &gt; 10g/dl Platelets &gt; 100.000/dl Alanine aminotransferase ( ALT ) ≤ 2.5 x upper limit normal ( ULN ) Creatinine ≤ 1.3 x ULN 5 . CD4 T cell count ≥500 cells/mm3 1 . Positive pregnancy test . 2 . Presence resistance drug mutation screen genotype 3 . History autoimmune disease HIVrelated autoimmune disease . 4 . Treatment cancer lymphoproliferative disease within 1 year study entry 5 . Any prior therapy , opinion investigator , would make individual unsuitable study influence result study 6 . Current recent use ( within last 3 month ) interferon systemic corticosteroid immunosuppressive agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>Early treatment</keyword>
	<keyword>Romidepsin</keyword>
	<keyword>HDACi</keyword>
	<keyword>Therapeutic Vaccines</keyword>
	<keyword>HIVconsv</keyword>
	<keyword>HIV reservoir</keyword>
	<keyword>Population PK/PD analysis</keyword>
</DOC>